**Appendix A**

**POST-COVID NEPHROLOGICAL PROTOCOL**

1. AGE: RACE:
2. GENDER ( ) FEM ( ) MAL
3. CONFIRMATORY EXAMINATION: DATE:
4. COMORBIDITIES:

( )DIABETES MELLITUS

( )SYSTEMIC ARTERIAL HYPERTENSION

( )CORONARY ARTERY DISEASE

( )OVERWHEIGHT/OBESITY BMI: \_\_\_\_\_\_\_\_\_

( ) COPD /ASTHMA/PNEUMOPATHY

( )VASCULOPATHY

( ) SMOKING

( ) OTHERS : \_\_\_\_\_\_\_\_\_\_\_

1. USED ACEI OR ARB DURING ILLNESS: ( ) YES ( ) NO
2. NEED FOR HOSPITALIZATION ( ) YES ( ) NO

7. NEED FOR HEMODIALYSIS DURING HOSPITALIZATION ( ) YES ( ) NO

1. INFORMATIONS ABOUT MEDICAL TREATMENT DURING COVID-19

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. CURRENT SYMPTOMS

( ) SAH / ARTERIAL PRESSURE: \_\_\_\_\_\_\_\_

( ) HEMATURIA

( ) EDEMA

( ) PROTEINURIA

( ) OTHERS \_\_\_\_\_\_\_\_\_\_\_

1. CURRENT TREATMENTS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
2. NEED FOR FOLLOW-UP WITH NEPHROLOGIST ( ) YES ( ) NO
3. LABORATORY

**Table A1.** Laboratory parameters

|  |  |
| --- | --- |
|  | DATE |
| HEMOGRAM |  |
| TGP/TG0 |  |
| ALKALINE PHOSPHATASE |  |
| GAMMA GT |  |
| UREA |  |
| CREATININE |  |
| ESR |  |
| RCP |  |
| ColT/HDL/LDL |  |
| TRIGLYCERIDES |  |
| GLUCOSE |  |
| FERRITIN |  |
| CPK |  |
| SODIUM |  |
| POTASSIUM |  |
| LDH |  |
| aPTT/PT |  |
| ALBUMIN |  |
| URINE TEST |  |
| Protein URINE |  |
| RedBloodCels URINE |  |
| Gluc URINE |  |
| GLYCATEDHEMOG |  |

TGO, mean oxaloacetic transaminase; TGP, mean pyruvic transaminase; ESR, erythrocyte sedimentation rate; RCP, mean C-reactive protein; ColT, mean total cholesterol; HDL, mean high density lipoproteins; LDL, mean low density lipoproteins; CPK, mean creatine phosphokinase; LDH, mean lactate dehydrogenase; APTT, activated partial thromboplastin time; PT, prothrombin time.

OBSERVATIONS:

REFERRAL: